University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Rahul Aggarwal, MD

Rahul Aggarwal, MD

Associate Director for Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center; Associate Professor of Hematology/Oncology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California San Francisco. My clinical practice focuses on patients with advanced solid tumor malignancies with a particular emphasis on genitourinary malignancies including prostate, kidney, bladder, and testicular cancer. I serve as the Co-Leader for the GU Medical Oncology program at UCSF.

My research focus is on developing novel therapies and imaging modalities for patients with advanced solid tumor malignancies, with a focus on patients with advanced prostate cancer.

Education

Northwestern University, Evanston, IL, BA, 1999-2002, Psychology
Northwestern University Feinberg School of Medicine, Chicago, IL, MD, 2002-2006, Medicine

Honors & Awards

  • 2001
    James Alton James Scholarship, Northwestern University
  • 2002
    James A. Patten Scholarship, Northwestern University
  • 2002
    Phi Beta Kappa Centennial Award, Northwestern University
  • 2002
    Summa Cum Laude, Northwestern University
  • 2004
    Department of Medicine Chairman’s Award, Northwestern University School of Medicine
  • 2005
    Member Alpha Omega Alpha medical honor society
  • 2011
    Pfizer Fellowships in Oncology Award in collaboration with UCSF Division of Hematology/Oncology, Department of Medicine
  • 2012
    Young Investigator Award, American Society of Clinical Oncology/Conquer Cancer Foundation
  • 2012
    Inaugural Recipient, Ronald A. Rosenberg Fellowship in Genitourinary Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2013
    Alliance Cooperative Group Scholar Award
  • 2014
    The Sence Foundation Award
  • 2015
    Prostate Cancer Foundation Young Investigator Award
  • 2016
    Department of Defense Prostate Cancer Research Program Physician Research Training Award
  • 2016
    UCSF Helen Diller Family Early Phase Clinical Research Support Grant
  • 2016
    National Cancer Institute Cancer Clinical Investigator Team Leadership
    Award

Selected Publications

  1. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig MB, Gleave ME, Evans CP, Lara PN, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. Autoantibody landscape in patients with advanced prostate cancer. Clin Cancer Res. 2020 Sep 23.
    View on PubMed
  2. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Parker MFL, Blecha JE, Drake CR, VanBrocklin HF, Ruiz DG, Jacobson MP, Aggarwal R, Behr SC, Flavell RR, Wilson DM, Seo Y, Evans MJ. The synthesis and structural requirements for measuring glucocorticoid receptor expression in vivo with (±)-11C-YJH08 PET. J Nucl Med. 2020 Sep 04.
    View on PubMed
  3. Han HJ, Li YR, Roach M, Aggarwal R. Dramatic response to combination pembrolizumab and radiation in metastatic castration resistant prostate cancer. Ther Adv Med Oncol. 2020; 12:1758835920936084.
    View on PubMed
  4. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Sep 01; 26(17):4616-4624.
    View on PubMed
  5. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2020 Jul 21.
    View on PubMed
  6. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 Jul 02.
    View on PubMed
  7. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 06 02; 117(22):12315-12323.
    View on PubMed
  8. Carneiro BA, Lotan TL, de Souza A, Aggarwal R. Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer. Am Soc Clin Oncol Educ Book. 2020 May; 40:e319-e332.
    View on PubMed
  9. Huang Y, Zhao N, Wang YH, Truillet C, Wei J, Blecha JE, VanBrocklin HF, Seo Y, Sayeed M, Feldman BJ, Aggarwal R, Behr SC, Shao H, Wilson DM, Villanueva-Meyer JE, Gestwicki JE, Evans MJ. A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chem Biol. 2020 06 19; 15(6):1381-1391.
    View on PubMed
  10. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Apr 14.
    View on PubMed
  11. Seo Y, Khalighi MM, Wangerin KA, Deller TW, Wang YH, Jivan S, Kohi MP, Aggarwal R, Flavell RR, Behr SC, Evans MJ. Quantitative and Qualitative Improvement of Low-Count [68Ga]Citrate and [90Y]Microspheres PET Image Reconstructions Using Block Sequential Regularized Expectation Maximization Algorithm. Mol Imaging Biol. 2020 02; 22(1):208-216.
    View on PubMed
  12. Gilligan T, Lin DW, Aggarwal R, Chism D, Cost N, Derweesh IH, Emamekhoo H, Feldman DR, Geynisman DM, Hancock SL, LaGrange C, Levine EG, Longo T, Lowrance W, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Saylor P, Sircar K, Smith DC, Tzou K, Vaena D, Vaughn D, Yamoah K, Yamzon J, Johnson-Chilla A, Keller J, Pluchino LA. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 12; 17(12):1529-1554.
    View on PubMed
  13. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323.
    View on PubMed
  14. Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol. 2020 03; 38(3):83-93.
    View on PubMed
  15. Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2020 06; 23(2):269-276.
    View on PubMed
  16. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571.
    View on PubMed
  17. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240.
    View on PubMed
  18. Mehnert JM, Varga A, Brose MS, Aggarwal RR, Lin CC, Prawira A, de Braud F, Tamura K, Doi T, Piha-Paul SA, Gilbert J, Saraf S, Thanigaimani P, Cheng JD, Keam B. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer. BMC Cancer. 2019 Mar 04; 19(1):196.
    View on PubMed
  19. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538.
    View on PubMed
  20. Zhu Z, Zhu X, Ohliger MA, Tang S, Cao P, Carvajal L, Autry AW, Li Y, Kurhanewicz J, Chang S, Aggarwal R, Munster P, Xu D, Larson PEZ, Vigneron DB, Gordon JW. Coil combination methods for multi-channel hyperpolarized 13C imaging data from human studies. J Magn Reson. 2019 04; 301:73-79.
    View on PubMed

Go to UCSF Profiles, powered by CTSI